Literature DB >> 817960

Impaired lithocholate sulfation in the rhesus monkey: a possible mechanism for chenodeoxycholate toxicity.

T R Gadacz, R N Allan, E Mack, A F Hofmann.   

Abstract

Radioactive lithocholate was administered intravenously to female rhesus monkeys with an exteriorized enterohepatic circulation, and the chemical form of biliary radioactivity was defined by thin layer chromatography. Most radioactivity was excreted in bile in the form of unsulfated conjugates (77%), indicating impaired sulfation relative to published data for man. Defective sulfation of lithocholate, the major bacterial biotransformation product of chenodeoxycholic acid, can explain accumulation of lithocholate in the enterohepatic circulation and provide a possible mechanism for the hepatotoxicity observed during chenodeoxycholic acid administration to the nonhuman primate.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 817960

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  14 in total

1.  Clinical conference.

Authors:  L J Schoenfield; P H Key; M J Coyne; J Panish; J A Hamlin; J M Shore; G Berci
Journal:  Am J Dig Dis       Date:  1978-08

Review 2.  Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II.

Authors:  W H Bachrach; A F Hofmann
Journal:  Dig Dis Sci       Date:  1982-09       Impact factor: 3.199

3.  Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR).

Authors:  Junichiro Sonoda; Wen Xie; John M Rosenfeld; Joyce L Barwick; Philip S Guzelian; Ronald M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

4.  Lithocholate metabolism during chemotherapy for gallstone dissolution. 2. Absorption and sulphation.

Authors:  R N Allan; J L Thistle; A F Hofmann
Journal:  Gut       Date:  1976-06       Impact factor: 23.059

5.  Bile acid conjugation in the chimpanzee: effective sulfation of lithocholic acid.

Authors:  M Schwenk; A F Hofmann; G L Carlson; J A Carter; F Coulston; H Greim
Journal:  Arch Toxicol       Date:  1978-04-27       Impact factor: 5.153

6.  Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study.

Authors:  U Leuschner; M Leuschner; J Sieratzki; W Kurtz; K Hübner
Journal:  Dig Dis Sci       Date:  1985-07       Impact factor: 3.199

7.  Sulfation of lithocholate as a possible modifier of chenodeoxycholic acid-induced elevations of serum transaminase in patients with gallstones.

Authors:  J W Marks; S O Sue; B J Pearlman; G G Bonorris; P Varady; J M Lachin; L J Schoenfield
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

Review 8.  Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.

Authors:  J H Iser; A Sali
Journal:  Drugs       Date:  1981-02       Impact factor: 9.546

9.  Relationship between serum and biliary bile acids as an indicator of chenodeoxycholic and ursodeoxycholic acid-induced hepatotoxicity in the rhesus monkey.

Authors:  F Bazzoli; A Roda; H Fromm; R P Sarva; E Roda; L Barbara
Journal:  Dig Dis Sci       Date:  1982-05       Impact factor: 3.199

10.  Fecal bile acid excretion pattern in colonic cancer patients.

Authors:  N F Breuer; P Dommes; S Jaekel; H Goebell
Journal:  Dig Dis Sci       Date:  1985-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.